Browsing Tag
Inc.
196 posts
An EV maker just bought a biotech to go all-in on crypto—Can Faraday Future’s $41 million gamble actually pay off?
Faraday Future’s $41M Qualigen deal will rebrand QLGN as CXC10 for Web3. See how this pivot could reshape the EV maker’s growth engine—full analysis inside.
Amazon sets ‘Prime Big Deal Days’ for October 7–8 to jump-start 2025 holiday shopping
Amazon confirms Prime Big Deal Days for Oct 7–8, with AI shopping tools, early deals, and stock momentum shaping this year’s holiday retail rush.
PNC Financial’s $4.1bn FirstBank acquisition to put it on top in Colorado and deepen Arizona expansion
PNC Bank’s $4.1B acquisition of FirstBank triples its Colorado footprint and expands Arizona reach. Find out what this means for investors and customers.
Nexstar bets $6.2bn on local news: Will its TEGNA buyout spark a new era in broadcast media?
Nexstar’s $6.2B acquisition of TEGNA could reshape U.S. local media, boost local news, and challenge big tech’s dominance. Will the bet pay off? Read more.
Why UScellular’s breakup with T-Mobile sets the stage for Array’s tower growth strategy
T-Mobile acquires UScellular’s wireless business for $4.3B; Array pivots to tower growth with 4,400 sites. Find out what this means for investors.
Why Thoma Bravo is backing Trading Technologies’ SaaS growth in capital markets
Thoma Bravo partners with 7RIDGE to support Trading Technologies’ expansion in capital markets infrastructure. Find out what this deal means for the SaaS leader.
Why Ramp’s $22.5bn valuation has investors chasing the future of AI‑driven expense management
Ramp raises $500M at a $22.5B valuation to scale autonomous AI agents for finance. Find out how Ramp Business Corporation is changing workflows today.
UScellular stock surges as FCC clears $4.4bn T-Mobile deal: Is tower leasing the next growth engine?
UScellular gains FCC approval to sell wireless assets to T-Mobile. Find out what this means for 5G expansion, spectrum assets, and tower revenue growth.
CERo Therapeutics gets FDA boost for CER-1236, eyes breakthrough in AML cell therapy
CERo Therapeutics secures FDA orphan drug status for CER-1236 in AML, advancing its novel CER-T immunotherapy platform. Read what this means for investors.
Ajinomoto strengthens U.S. pharma operations with $2.1m lab upgrade in Raleigh
Ajinomoto Health & Nutrition (TYO: 2802) opens a $2.1M QC lab in Raleigh, strengthening global API leadership. Pharma-grade amino acid growth in focus.